Last reviewed · How we verify

NCT05204940: OPT-Neuro

Longitudinal Observational Biomarker Study

Completed Last updated 25 November 2024
What this trial tests

trial testing Mechanisms of Late life depression (LLD)-dementia through functional Magnetic Resonance Imaging (fMRI) in Depression in 506 participants. Completed in 31 July 2024.

Timeline
27 September 2017
Primary endpoint
31 July 2024
31 July 2024

Quick facts

Lead sponsorCentre for Addiction and Mental Health
StatusCompleted
Study typeOBSERVATIONAL
Enrollment506
Start date27 September 2017
Primary completion31 July 2024
Estimated completion31 July 2024
Sites5 locations across Canada, United States

Drugs / interventions tested

Conditions studied

Sponsor

Centre for Addiction and Mental Health — full company profile →

Who can join

60 and older, any sex, with Depression or Dementia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to test whether treatment-resistant late life depression is associated with declines in memory and attention and brain structure and function.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Depression

Currently open trials in the same condition.

Other Centre for Addiction and Mental Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05204940.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing